InSite Vision develops novel ophthalmic products designed to treat a growing range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. InSite utilizes its proprietary drug delivery platform, DuraSite. DuraSite is a synthetic polymer of cross-linked polyacrylic acid that stabilizes small molecules, like the antibiotic azithromycin, in an aqueous matrix. The platform can be customized to deliver a wide range of medications. InSite has also developed AzaSite for the treatment of bacterial conjunctivitis and is licensed by Akorn, Inc. (NASDAQ:AKRX). In addition, InSite has Besivance, a formulation of besifloxacin using the DuraSite delivery platform. Besivance was developed by Baush and Lomb. Originally trading on AMEX, when that Exchange ceased operations, the firm moved to OTC. In 2015, three months after signing a deal to be bought by QLT Inc., publicly traded ophthalmology firm InSite Vision Inc. decided instead on a $46mm cash acquisition by Indian drug company Sun Pharmaceutical Industries Ltd.
